A dramatic fetal outcome following transplacental transfer of dasatinib

Anti-Cancer Drugs

Volumn 23, Issue 7, 2012, Pages 754-757

  Berveiller, Paul ^a   Andreoli, Annalisa ^c   Mir, Olivier ^b   Anselem, Olivia ^b   Delezoide, Anne Lise ^b   Sauvageon, Hélène ^c   Chapuis, Nicolas ^b   Tsatsaris, Vassilis ^a,b  

^a INSERM   (France)

^b Université Paris Descartes ^*  (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

chronic myeloid leukemia; dasatinib; placenta; pregnancy neoplastic complications; tyrosine kinase inhibitors

Indexed keywords

CHORIONIC GONADOTROPIN; DASATINIB; IMATINIB;

ABDOMINAL PAIN; ADULT; AMNIOCENTESIS; AMNION FLUID; ARTICLE; ASCITES; BIOLOGICAL MONITORING; BLAST CELL; BLOOD SAMPLING; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; EDEMA; FEMALE; FETUS BLOOD; FETUS HYDROPS; FETUS OUTCOME; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HEMATOPOIESIS; HORMONE BLOOD LEVEL; HUMAN; HYPERTELORISM; KARYOTYPE; LEUKOCYTE COUNT; LEUKOPENIA; MATERNAL PLASMA; MITOSIS; NAUSEA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLACENTAL TRANSFER; PLEURA EFFUSION; PREGNANCY TERMINATION; PREGNANT WOMAN; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; VOMITING;

FEMALE; FETUS; HUMANS; HYDROPS FETALIS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOPENIA; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863574280     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328352a8fe     Document Type: Article

References (15)

1. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18:569-584. (Pubitemid 38969132)
2. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-abl mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011; 117:1800-1811.
3. Food and Drug Administration. Available at http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4325b-08-03-Imatinib Mesylate AE Review.pdf. [Accessed 14 December 2011].
4. Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 2009; 7:1050-1058.
5. Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505-5508.
6. Cole S, Kantarjian H, Ault P, Cortes JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: A case report and review of the literature. Clin Lymphoma Myeloma 2009; 9:324-327.
7. Food and Drug Administration. Available at http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/021986s7s8lbl.pdf. [Accessed 14 December 2011].
8. He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 2008; 36:2564-2570.
9. Kroll T, Ames MB, Pruett JA, Fenske TS. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 2010; 51:1751-1753.
10. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, et al. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010; doi: 10.1155/ 2010/136252 [Epub 7 March 2010].
11. Cortes J, O'Brien S, Ault P, Borthakur G, Jabbour E, Bradley-GARELIK B, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 2008; 112:ASH Annual Meeting Abstract 3230.
12. Conchon M, Sanabani SS, Bendit I, Santos FM, Serpa M, Dorliac-LLACER PE. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: Case study. J Hematol Oncol 2009; 2:42.
13. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200-1206. (Pubitemid 351833788)
14. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-Resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-4505. (Pubitemid 40740783)
15. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-Phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-2270.